Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

United Neuroscience To Move Forward Alzheimer's Vaccine After Promising Phase IIa

Executive Summary

It's early days yet and Alzheimer's is a field littered with failures, but the latest results for the vaccine UB-311 support advancing development.

Advertisement

Related Content

J.P. Morgan Roundtable: The Regulatory Role In Accelerating Complex Therapies
J.P. Morgan Roundtable: The Regulatory Role In Accelerating Complex Therapies
J.P. Morgan Roundtable: Financing Challenges, And Opportunities, For Complex Therapies
Biogen's Busy Pipeline: Continued Confusion On BAN2401, But Other Irons In The Fire
M&A Pressure Mounts For Merck & Co After Alzheimer's Drug Dismissed
Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success
Wyeth/Elan Submit Pharmacogenomics Study Report From Alzheimer’s Trial To FDA

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124500

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel